Harbour BioMed

Industry

  • Biotechnology
    • Transgenics
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
  • Pharmaceuticals

Other Names/Subsidiaries

  • Harbour Antibodies, Hbm Holdings
  • Nona Biosciences
See more in Biomedtracker

Latest on Harbour BioMed

Scrip

AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation

 
• By Dexter Jie Yan

While the world’s pharma industry has increasingly connected with Chinese-developed me-too or fast-follower novel drugs over the past few years, AstraZeneca, which already has more than three decades

Scrip

AstraZeneca Expands Emphasis On China, Already A Key Market

 
• By Joseph Haas

AstraZeneca already considers China one of its most important markets and is increasing its focus there, announcing a $2.5bn research and development investment in Beijing along with three partnership

Scrip

Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary

 
• By Joseph Haas, Vibha Ravi, Lisa Takagi, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C

Scrip

Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku

 
• By Joseph Haas, Lisa Takagi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regenxbio Calls On Nippon Shinyaku To